Biofrontera Statistics
Share Statistics
Biofrontera has 9.45M
shares outstanding. The number of shares has increased by 74.36%
in one year.
| Shares Outstanding | 9.45M |
| Shares Change (YoY) | 74.36% |
| Shares Change (QoQ) | 14.51% |
| Owned by Institutions (%) | 0.74% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 343 |
| FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 119.29K, so 1.26% of the outstanding
shares have been sold short.
| Short Interest | 119.29K |
| Short % of Shares Out | 1.26% |
| Short % of Float | 1.26% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -338.58 and the forward
PE ratio is -0.98.
Biofrontera's PEG ratio is
3.39.
| PE Ratio | -338.58 |
| Forward PE | -0.98 |
| PS Ratio | 161.19 |
| Forward PS | 0 |
| PB Ratio | 1356.37 |
| P/FCF Ratio | -584.9 |
| PEG Ratio | 3.39 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Biofrontera.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72,
with a Debt / Equity ratio of 1.11.
| Current Ratio | 1.72 |
| Quick Ratio | 1.17 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | -0.34 |
| Debt / FCF | -0.48 |
| Interest Coverage | -8.17 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $405,467.39 |
| Profits Per Employee | $-193,032.61 |
| Employee Count | 92 |
| Asset Turnover | 1.69 |
| Inventory Turnover | 2.8 |
Taxes
| Income Tax | 22K |
| Effective Tax Rate | -0.12% |
Stock Price Statistics
The stock price has increased by -44.66% in the
last 52 weeks. The beta is 0.38, so Biofrontera's
price volatility has been higher than the market average.
| Beta | 0.38 |
| 52-Week Price Change | -44.66% |
| 50-Day Moving Average | 0.75 |
| 200-Day Moving Average | 0.97 |
| Relative Strength Index (RSI) | 32.05 |
| Average Volume (20 Days) | 115,361 |
Income Statement
In the last 12 months, Biofrontera had revenue of 37.3M
and earned -17.76M
in profits. Earnings per share was 0.
| Revenue | 37.3M |
| Gross Profit | 18.7M |
| Operating Income | -17.21M |
| Net Income | -17.76M |
| EBITDA | -14.44M |
| EBIT | -15.63M |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 5.91M in cash and 4.92M in
debt, giving a net cash position of 983K.
| Cash & Cash Equivalents | 5.91M |
| Total Debt | 4.92M |
| Net Cash | 983K |
| Retained Earnings | -117.41M |
| Total Assets | 16.59M |
| Working Capital | 4.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -10.27M
and capital expenditures -10K, giving a free cash flow of -10.28M.
| Operating Cash Flow | -10.27M |
| Capital Expenditures | -10K |
| Free Cash Flow | -10.28M |
| FCF Per Share | 0 |
Full Cash Flow StatementMargins
Gross margin is 50.12%, with operating and profit margins of -46.14% and -47.61%.
| Gross Margin | 50.12% |
| Operating Margin | -46.14% |
| Pretax Margin | -47.55% |
| Profit Margin | -47.61% |
| EBITDA Margin | -38.71% |
| EBIT Margin | -46.14% |
| FCF Margin | -27.56% |
